- Home
- CRVS vs LFMD Comparison
CRVS vs LFMD Comparison
Compare CRVS & LFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- LFMD
- Stock Information
- Founded
- CRVS 2014
- LFMD 1994
- Country
- CRVS United States
- LFMD United States
- Employees
- CRVS N/A
- LFMD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- LFMD Medical/Nursing Services
- Sector
- CRVS Health Care
- LFMD Health Care
- Exchange
- CRVS Nasdaq
- LFMD Nasdaq
- Market Cap
- CRVS 257.0M
- LFMD N/A
- IPO Year
- CRVS 2016
- LFMD N/A
- Fundamental
- Price
- CRVS $3.05
- LFMD $5.03
- Analyst Decision
- CRVS Strong Buy
- LFMD Strong Buy
- Analyst Count
- CRVS 5
- LFMD 7
- Target Price
- CRVS $12.63
- LFMD $11.57
- AVG Volume (30 Days)
- CRVS 726.0K
- LFMD 1.3M
- Earning Date
- CRVS 05-05-2025
- LFMD 05-07-2025
- Dividend Yield
- CRVS N/A
- LFMD N/A
- EPS Growth
- CRVS N/A
- LFMD N/A
- EPS
- CRVS N/A
- LFMD N/A
- Revenue
- CRVS N/A
- LFMD $212,453,838.00
- Revenue This Year
- CRVS N/A
- LFMD $29.08
- Revenue Next Year
- CRVS N/A
- LFMD $18.81
- P/E Ratio
- CRVS N/A
- LFMD N/A
- Revenue Growth
- CRVS N/A
- LFMD 39.27
- 52 Week Low
- CRVS $1.30
- LFMD $3.99
- 52 Week High
- CRVS $10.00
- LFMD $12.88
- Technical
- Relative Strength Index (RSI)
- CRVS 31.75
- LFMD 42.25
- Support Level
- CRVS $2.56
- LFMD $4.57
- Resistance Level
- CRVS $3.31
- LFMD $5.35
- Average True Range (ATR)
- CRVS 0.35
- LFMD 0.38
- MACD
- CRVS -0.07
- LFMD -0.07
- Stochastic Oscillator
- CRVS 24.02
- LFMD 31.65
Stock Price Comparison Chart: CRVS vs LFMD
■ CRVS
■ LFMD
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Share on Social Networks:
0